Clinical Research Directory
Browse clinical research sites, groups, and studies.
Research of SORD-CMT Natural History and Epalrestat Treatment
Sponsor: The Third Xiangya Hospital of Central South University
Summary
Charcot-Marie-Tooth disease (CMT) is a group of the most common hereditary peripheral neuropathy with high clinical and genetic heterogeneity. Biallelic pathogenic variants in SORD gene leading to loss of function of SORD protein cause axonal degeneration. Current research suggests that SORD-CMT2 may be the most common subtype of AR-CMT2. The primary purpose of this study is to explore the natural history of SORD-CMT2 patients by detecting the ONLS scale score and serum sorbitol level changes at 6th, 12th, 24th, and 36th months and to evaluate the effectiveness and safety of epalrestat. Patients with strong treatment willingness and voluntary purchase of drugs are included in the epalrestat treatment group, and patients without drug treatment willingness are included in the control group. Patients in the drug treatment group take epalrestat (50 mg) orally three times daily. This study is expected to be carried out simultaneously in 5 hospitals in mainland China. About 30 SORD-CMT2 patients will be enrolled in this study, and the study period will be 36 months.
Official title: Multi-center Study of Natural History of SORD-related Charcot-Marie-Tooth Disease and Epalrestat Treatment
Key Details
Gender
All
Age Range
14 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-04
Completion Date
2026-04
Last Updated
2023-04-18
Healthy Volunteers
No
Conditions
Interventions
Epalrestat
Patients in the treatment group are intervened with Epalrestat tablets.